Here's the announcement from two weeks ago, Zygel is patent protected for autism while our BTX's have Permetrex in their patent applications for a variety of skin conditions and are well ahead in their development as Zygel' s Phase2 trial results are not expected till the second half of 2020.
https://zynerba.com/zynerba-pharmaceuticals-initiates-phase-2-trial-of-zygel-in-autism-spectrum-disorder/
https://zynerba.com/zynerba-pharmaceuticals-receives-new-u-s-patent-for-treatment-of-fragile-x-syndrome-with-cannabidiol/
Botanix Takeover, page-18
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $707.4M | |||
| Open | High | Low | Value | Volume |
| 31.5¢ | 32.5¢ | 30.5¢ | $1.502M | 4.765M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 189068 | 31.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.0¢ | 535424 | 6 |
View Market Depth
| Last trade - 16.10pm 21/11/2024 (20 minute delay) ? |
| BOT (ASX) Chart |
